Literature DB >> 7082042

Gonadal function after combination chemotherapy for Hodgkin's disease in childhood.

E Whitehead, S M Shalet, P H Jones, C G Beardwell, D P Deakin.   

Abstract

The effect of quadruple chemotherapy (mustine, vincristine, procarbazine, and prednisolone) on gonadal function was investigated in 15 males and 2 females treated for Hodgkin's disease during childhood. The 2 females have regular menstrual cycles with evidence of ovulation in one. Twelve of the males have shown normal progression of pubertal development since completing their treatment. Nine out of 10 late pubertal or adult subjects had small testes but only one developed gynaecomastia. All 4 prepubertal subjects had normal basal and peak gonadotrophin responses to luteinising hormone-releasing hormone. Nine of the 12 subjects studied during puberty or adulthood had either an increased basal serum follicle-stimulating hormone (FSH) level or an exaggerated FSH response to luteinising hormone-releasing hormone. Each of the 6 males who provided semen for analysis was azoospermic after an interval of between 2.4 and 8 (mean 5.3) years after completion of treatment. We conclude that severe testicular damage is common after treatment with mustine, vincristine, procarbazine, and prednisolone in childhood. The germinal epithelium is particularly vulnerable and the resultant azoospermia is likely to be irreversible. The Leydig cells are less susceptible to cytotoxic-induced damage. Pubertal development is normal and there is no indication for androgen replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082042      PMCID: PMC1627621          DOI: 10.1136/adc.57.4.287

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Antineoplastic drug effects on spermatogenesis studied by velocity sedimentation cell separation.

Authors:  I P Lee; R L Dixon
Journal:  Toxicol Appl Pharmacol       Date:  1972-09       Impact factor: 4.219

2.  Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma.

Authors:  P Richter; J C Calamera; M C Morgenfeld; A L Kierszenbaum; J C Lavieri; R E Mancini
Journal:  Cancer       Date:  1970-05       Impact factor: 6.860

3.  Effects of procarbazine on spermatogenesis determined by velocity sedimentation cell separation technique and serial mating.

Authors:  I P Lee; R L Dixon
Journal:  J Pharmacol Exp Ther       Date:  1972-05       Impact factor: 4.030

4.  Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease.

Authors:  R J Sherins; C L Olweny; J L Ziegler
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

5.  Effect of prednisolone upon normal and pathologic human spermatogenesis.

Authors:  R E Mancini; J C Lavieri; F Muller; J A Andrada; D J Saraceni
Journal:  Fertil Steril       Date:  1966 Jul-Aug       Impact factor: 7.329

6.  Response of plasma LH and FSH to synthetic LH-RH in children at various pubertal stages.

Authors:  Z Dickerman; R Prager-Lewis; Z Laron
Journal:  Am J Dis Child       Date:  1976-06

7.  A simple method for the assay of eight steroids in small volumes of plasma.

Authors:  D C Anderson; B R Hopper; B L Lasley; S S Yen
Journal:  Steroids       Date:  1976-08       Impact factor: 2.668

8.  Return of spermatogenesis after stopping cyclophosphamide therapy.

Authors:  J D Buchanan; K F Fairley; J U Barrie
Journal:  Lancet       Date:  1975-07-26       Impact factor: 79.321

9.  Pituitary function after treatment of intracranial tumours in children.

Authors:  S M Shalet; C G Beardwell; P H Morris-Jones; D Pearson
Journal:  Lancet       Date:  1975-07-19       Impact factor: 79.321

10.  Carcinogenic and other adverse effects of procarbazine in nonhuman primates.

Authors:  S M Sieber; P Correa; D W Dalgard; R H Adamson
Journal:  Cancer Res       Date:  1978-07       Impact factor: 12.701

View more
  12 in total

1.  Cancer, chemotherapy, and fertility.

Authors:  J Waxman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

Review 2.  Hodgkin's disease.

Authors:  T S Vats
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

3.  Chemotherapy and irradiation in childhood Hodgkin's disease.

Authors:  B Robinson; J Kingston; R Nogueira Costa; J S Malpas; A Barrett; T J McElwain
Journal:  Arch Dis Child       Date:  1984-12       Impact factor: 3.791

Review 4.  Reproductive outcomes for survivors of childhood cancer.

Authors:  Melissa M Hudson
Journal:  Obstet Gynecol       Date:  2010-11       Impact factor: 7.661

Review 5.  Late effects of antineoplastic therapy in childhood on growth and endocrine function.

Authors:  W H Wallace; C J Kelnar
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

6.  Failure to preserve fertility in patients with Hodgkin's disease.

Authors:  J H Waxman; R Ahmed; D Smith; P F Wrigley; W Gregory; S Shalet; D Crowther; L H Rees; G M Besser; J S Malpas
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Toana Kawashima; Marilyn Stovall; Wendy Leisenring; Charles A Sklar; Ann C Mertens; Sarah S Donaldson; Julianne Byrne; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  Gonadal dysfunction after treatment of intracranial tumours.

Authors:  E A Livesey; C G Brook
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

Review 9.  Critical windows of exposure for children's health: the reproductive system in animals and humans.

Authors:  J L Pryor; C Hughes; W Foster; B F Hales; B Robaire
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

Review 10.  Abnormalities of growth and gonadal function in children treated for malignant disease: a review.

Authors:  S M Shalet
Journal:  J R Soc Med       Date:  1982-08       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.